Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

Source: COVID-19 Vaccine  Jul 15, 2020  3 years, 8 months, 4 weeks, 1 day, 23 hours, 36 minutes ago

COVID-19 Vaccine: Canadian Biopharmaceutical Company Medicago Launches Phase I Trial for Plant-Derived COVID-19 Vaccine Candidate

COVID-19 Vaccine: Canadian Biopharmaceutical Company Medicago Launches Phase I Trial for Plant-Derived COVID-19 Vaccine Candidate
Source: COVID-19 Vaccine  Jul 15, 2020  3 years, 8 months, 4 weeks, 1 day, 23 hours, 36 minutes ago
COVID- 19 Vaccine: Canadian biophamaceutical company Medicago that is based in Quebec with branches in the U.S. announced that it has begun Phase I clinical trial for its plant-derived COVID-19 vaccine candidate. It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.

Dr Nathalie Landry, Executive Vice-President, Scientific and Medical Affairs at Medicago told Thailand Medical News, We are thrilled to see our COVID-19 vaccine candidate enter the Phase I trial, and we look forward to obtaining safety and immunogenicity results in October. Our progress continues to demonstrate the value of Medicago’s unique plant-based vaccine technology.”
The launched Phase I clinical trial is a randomized, partially blinded study involving 180 healthy volunteers between the ages of 18 and 55. It is designed to evaluate doses of 3.75, 7.5 or 15 micrograms of the recombinant Coronavirus Virus-Like Particle (CoVLP) vaccine candidate by itself, or with an adjuvant in a prime-boost regimen.
The company is testing its vaccine candidate with two adjuvants separately – GSK’s (GlaxoSmithKline) proprietary pandemic adjuvant technology, as well as Dynavax’s CpG 1018. Utilizing an adjuvant can potentially boost the immune response of subjects and reduce the amount of antigen needed per dose. In turn, this allows for more vaccine doses to be produced.
Dr Bruce Clark, CEO of Medicago told Thailand Medical News, “Creating a sufficient supply of COVID-19 vaccines within the next year is a challenge which will require multiple approaches, with different technologies,”. “Our proven plant-based technology is capable of contributing to the collective solution to this public health emergency.”
Currently, Medicago is the only company with plant-based manufacturing technology that has completed Phase III clinical trials and pandemic Phase II clinical trials. The company intends to manufacture approximately 100 million doses of its vaccine by 2021.
Instead of using animal products of live viruses to create its products, Medicago uses Virus-Like Particles (VLPs) that mimic the shape and dimensions of a virus, which allows the body to recognize them and create an immune response in a non-infectious manner.
The biopharmaceutical company announced back on July 8 that it had entered a collaboration agreement with Dynavax to investigate an adjuvanted vaccine candidate to protect against COVID-19. As previously mentioned, Medicago is exploring the use of Dynavax’s CpG 1018 to enhance the immune response of its COVID-19 vaccine.
Ryan Spencer, Chief Executive Officer of Dynavax added, “The ability of CpG 1018 to enhance the immune response, as demonstrated in HEPLISAV-B, combined with the ability to scale-up manufacturing to produce large quantities quickly, makes it ideally suited in this environment where quantity, speed, and safety are all critical factors in addition to generating an effective immune response across all adult ages.”
GlaxoSmithKlineGSK and Medicago announced their new collaboration agreement back on July 7th which is looking int o the use of Medicago's recombinant CoVLPs with GSK's pandemic adjuvant system. Both companies intend to complete development and make the COVID-19 vaccine available in the first half of 2021, pending successful clinical development and regulatory considerations.
Dr Thomas Breuer, Chief Medical Officer, GSK Vaccines said, “This agreement paves the way for an innovative vaccine option combining a scalable plant-based antigen technology with an adjuvant which has pandemic dose sparing capability. If successful, it will be a meaningful contributor in the fight against COVID-19. We strongly believe that multiple vaccines are needed, including post-pandemic vaccines. This plant-based technology also shows promise beyond COVID-19 and has the potential to help prevent other infectious diseases.”
For more on COVID-19 Vaccine research, developments, progress and failures, keep on reading Thailand Medical News.